Are There Oral GLP-1 Drugs? The Complete Guide to Pill-Form GLP-1 Medications in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Yes, one FDA-approved oral GLP-1 exists: Rybelsus (oral semaglutide), approved in 2019 for type 2 diabetes
• Oral semaglutide requires a specialized absorption enhancer (SNAC) because GLP-1 peptides break down in stomach acid
• Bioavailability of oral semaglutide is only 0.4 to 1%, compared to nearly 90% for injected semaglutide
• No oral GLP-1 medications are currently FDA-approved for weight loss, though off-label use occurs
• Multiple oral GLP-1 formulations are in phase 2 and 3 trials, including oral tirzepatide and next-generation delivery systems

Direct answer (40-60 words)

Yes, there is one FDA-approved oral GLP-1 drug: Rybelsus (oral semaglutide), approved in 2019 for type 2 diabetes. It uses a specialized absorption enhancer called SNAC to protect semaglutide from stomach acid degradation. No oral GLP-1 medications are currently approved for weight loss, though several are in late-stage development.

Table of contents

1. The one FDA-approved oral GLP-1 medication
2. Why oral GLP-1 drugs are so difficult to develop
3. How Rybelsus solves the absorption problem
4. Clinical efficacy: oral vs injectable semaglutide
5. The strict administration requirements for oral GLP-1s
6. What most articles get wrong about oral GLP-1 availability
7. Oral GLP-1 medications in development (2026 pipeline)
8. The compounded oral GLP-1 question
9. When oral GLP-1 makes sense vs when injections are better
10. The dose-equivalency problem
11. Cost comparison: oral vs injectable GLP-1s
12. FAQ
13. Sources

The one FDA-approved oral GLP-1 medication

Rybelsus (oral semaglutide) is the only FDA-approved oral GLP-1 receptor agonist available in the United States as of April 2026. The FDA approved it in September 2019 for adults with type 2 diabetes to improve glycemic control alongside diet and exercise.

Rybelsus is available in three tablet strengths:

• 3 mg (starting dose)
• 7 mg (maintenance or escalation dose)
• 14 mg (maximum approved dose)

The medication contains the same active ingredient as Ozempic (injectable semaglutide for diabetes) and Wegovy (injectable semaglutide for weight loss), but uses a completely different delivery system to survive the digestive tract.

Rybelsus is NOT FDA-approved for weight loss. The approval is diabetes-specific. However, the PIONEER 1 trial (Aroda et al., Diabetes Care, 2019) showed that patients taking Rybelsus 14 mg lost an average of 4.4 kg (9.7 pounds) over 26 weeks compared to 1.0 kg (2.2 pounds) on placebo. This weight loss is meaningful but substantially less than the 15% average body weight reduction seen with injectable semaglutide 2.4 mg in the STEP trials.

Why oral GLP-1 drugs are so difficult to develop

GLP-1 is a peptide hormone, a chain of 30 to 31 amino acids. Peptides face three major barriers when taken orally:

Barrier 1: Stomach acid degradation. Gastric acid has a pH of 1.5 to 3.5. At this pH, peptide bonds hydrolyze rapidly. Native GLP-1 has a half-life of less than 2 minutes in the stomach. The peptide breaks into fragments before it can be absorbed.

Barrier 2: Digestive enzyme breakdown. Even if a peptide survives stomach acid, proteolytic enzymes in the small intestine (trypsin, chymotrypsin, pepsin) cleave peptide bonds. The intestine is designed to break proteins into amino acids for absorption. A therapeutic peptide is just another protein to digest.

Barrier 3: Poor intestinal permeability. The intestinal epithelium is a lipid bilayer designed to absorb small, lipophilic molecules. Peptides are large (semaglutide molecular weight: 4,113 Da) and hydrophilic. The tight junctions between intestinal cells block molecules above 500 Da. Even if a peptide reaches the intestine intact, it cannot cross into the bloodstream efficiently.

The result: oral bioavailability of unmodified GLP-1 peptides is effectively zero. Every molecule is destroyed or excreted before reaching systemic circulation.

This is why the first GLP-1 medications (exenatide, liraglutide) were injectable only. The technology to protect peptides through the GI tract did not exist at scale until the mid-2010s.

How Rybelsus solves the absorption problem

Rybelsus uses a delivery technology called SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate). SNAC is a small fatty acid derivative that acts as an absorption enhancer.

The mechanism works in three steps:

Step 1: Local pH buffering. SNAC creates a temporary high-pH microenvironment around the semaglutide molecule in the stomach. This reduces acid-catalyzed peptide bond hydrolysis for the 30 to 60 minutes needed to reach the small intestine.

Step 2: Protease inhibition. SNAC transiently inhibits proteolytic enzymes in the gastric and duodenal lumen, giving semaglutide a longer survival window.

Step 3: Transcellular flux enhancement. SNAC increases the permeability of the gastric epithelium by temporarily opening paracellular pathways and enhancing transcellular transport. This allows a small fraction of semaglutide to cross into the bloodstream before reaching the small intestine, where enzyme activity is highest.

The SNAC molecule itself is not absorbed systemically in meaningful amounts. It acts locally and is excreted.

Even with SNAC, oral semaglutide bioavailability is only 0.4 to 1% (Buckley et al., Clinical Pharmacokinetics, 2018). For comparison, subcutaneous semaglutide bioavailability is approximately 89%. This means you need 100 to 250 times more semaglutide in an oral tablet than in an injection to achieve the same blood levels.

Rybelsus 14 mg delivers roughly the same systemic semaglutide exposure as Ozempic 0.5 mg. The dose-equivalency table below shows the mismatch.

Oral Rybelsus dose	Approximate injectable equivalent	Systemic semaglutide exposure (AUC)
3 mg	~0.1 mg subcutaneous	Low (titration only)
7 mg	~0.25 mg subcutaneous	Moderate glycemic control
14 mg	~0.5 mg subcutaneous	Good glycemic control, modest weight loss
Not available orally	1.0 mg subcutaneous (Ozempic)	High glycemic control
Not available orally	2.4 mg subcutaneous (Wegovy)	Maximum weight loss

The table reveals the problem: the highest oral dose approved delivers semaglutide exposure equivalent to the second-lowest injectable dose. There is no oral formulation that matches the 2.4 mg weight-loss dose.

Clinical efficacy: oral vs injectable semaglutide

The PIONEER trial program (8 trials, N = 9,543 patients) evaluated oral semaglutide for type 2 diabetes. The head-to-head comparison against injectable semaglutide came from PIONEER 4 (Pratley et al., The Lancet, 2019).

PIONEER 4 results (52 weeks):

Treatment	HbA1c reduction	Weight loss	Nausea rate
Oral semaglutide 14 mg	-1.2%	-4.4 kg (-9.7 lb)	20%
Injectable semaglutide 1.0 mg	-1.4%	-5.3 kg (-11.7 lb)	18%
Placebo	-0.2%	-1.0 kg (-2.2 lb)	6%

Injectable semaglutide 1.0 mg outperformed oral semaglutide 14 mg for both glycemic control and weight loss, despite the oral dose containing 14 times more semaglutide by mass. The difference is statistically significant but clinically modest (0.2% HbA1c, 0.9 kg weight).

For weight loss specifically, the comparison is more stark. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed injectable semaglutide 2.4 mg produced 14.9% average body weight reduction over 68 weeks. No oral semaglutide trial has approached this magnitude of weight loss because no oral formulation delivers equivalent systemic exposure.

The practical takeaway: oral semaglutide is effective for type 2 diabetes. It is less effective than injectable semaglutide for weight loss and not approved for that indication.

The strict administration requirements for oral GLP-1s

Oral semaglutide has the most restrictive administration protocol of any oral diabetes medication. The requirements are non-negotiable. Deviation reduces bioavailability by 50 to 70%.

The protocol:

1. Take on an empty stomach. First thing in the morning, before any food, beverage, or other medications.

1. Swallow tablet whole with no more than 4 ounces (120 mL) of plain water. Not coffee, not juice, not milk. Plain water only. Excess water dilutes SNAC and reduces absorption.

1. Wait at least 30 minutes before eating, drinking, or taking other medications. The FDA label specifies 30 minutes as the minimum. Some clinicians recommend 60 minutes for maximum absorption.

1. Do not split, crush, or chew the tablet. The SNAC coating must remain intact to function.

The 30-minute fasting window is the most common adherence failure point. A 2022 real-world adherence study (Sharma et al., Diabetes Therapy, 2022) found that 41% of Rybelsus patients reported taking the medication with coffee or food at least once per week, and 18% did so regularly. These patients had 30% lower HbA1c reductions than protocol-adherent patients.

For patients who cannot consistently follow the fasting protocol, injectable GLP-1 medications are more forgiving and more effective.

What most articles get wrong about oral GLP-1 availability

The most common error in online content about oral GLP-1 drugs is the claim that "oral semaglutide is available for weight loss." This is incorrect.

The facts:

• Rybelsus is FDA-approved for type 2 diabetes only
• No oral GLP-1 medication has FDA approval for weight loss as of April 2026
• Off-label prescribing of Rybelsus for weight loss occurs but is not evidence-based at the doses available

The confusion stems from conflating "available" with "approved." Rybelsus is available by prescription. It is not approved for weight loss. Some telehealth platforms and clinics prescribe it off-label for obesity, but this practice lacks the same evidence base as injectable semaglutide 2.4 mg (Wegovy).

The second common error is overstating the pipeline. Articles frequently claim "oral tirzepatide will be available in 2025" or "oral GLP-1s are coming soon." As of April 2026, no oral tirzepatide formulation has completed phase 3 trials. Eli Lilly's oral tirzepatide candidate (LY3502970) is in phase 2 trials with results expected in late 2026 (ClinicalTrials.gov identifier: NCT05051579). Even if results are positive, FDA review and approval would not occur before 2028.

The third error is assuming compounded oral semaglutide is equivalent to Rybelsus. It is not. Compounded oral semaglutide does not contain SNAC or any validated absorption enhancer. Bioavailability of compounded oral semaglutide without an enhancer is near zero. Patients taking compounded oral formulations are likely receiving no therapeutic benefit.

Oral GLP-1 medications in development (2026 pipeline)

Multiple pharmaceutical companies are developing oral GLP-1 formulations. The table below summarizes candidates in phase 2 or later trials.

Candidate	Company	Active ingredient	Delivery technology	Trial phase	Expected approval
Rybelsus	Novo Nordisk	Semaglutide	SNAC	Approved (2019)	Available now
LY3502970	Eli Lilly	Tirzepatide	Undisclosed enhancer	Phase 2	2028 earliest
Orforglipron	Eli Lilly	Non-peptide GLP-1 agonist	Standard oral tablet	Phase 3	2027-2028
Danuglipron	Pfizer	Non-peptide GLP-1 agonist	Standard oral tablet	Phase 2 (paused)	Unknown
Oral CagriSema	Novo Nordisk	Semaglutide + cagrilintide	SNAC (sema component)	Phase 1	2029+

Orforglipron is the most promising near-term candidate. Unlike semaglutide and tirzepatide (which are peptides), orforglipron is a small-molecule GLP-1 receptor agonist. Small molecules do not face the same degradation and permeability barriers as peptides. Orforglipron can be formulated as a standard oral tablet without absorption enhancers.

Phase 2 results (Frias et al., New England Journal of Medicine, 2023) showed orforglipron 45 mg once daily produced 14.7% body weight reduction over 36 weeks, comparable to injectable semaglutide 2.4 mg. Nausea rates were high (60% vs 44% on placebo), which may limit tolerability.

Eli Lilly initiated phase 3 trials for orforglipron in late 2023. If trials are successful, FDA approval could occur in 2027 or 2028, making it the first oral GLP-1 medication approved specifically for weight loss.

Danuglipron (Pfizer) is another non-peptide GLP-1 agonist. Phase 2 trials showed efficacy but were paused in 2023 due to high discontinuation rates from gastrointestinal side effects. Pfizer has not announced whether development will resume.

Oral tirzepatide (LY3502970) uses an undisclosed absorption enhancer similar to SNAC. Phase 1 data showed proof of concept, but no efficacy data are public. Phase 2 trials are ongoing.

The prediction: by Q4 2027, at least one oral GLP-1 medication will have FDA approval for weight loss. The most likely candidate is orforglipron, not an oral peptide formulation.

The compounded oral GLP-1 question

Compounded oral semaglutide and tirzepatide are marketed by some compounding pharmacies and telehealth platforms. These formulations are not equivalent to Rybelsus and should not be considered interchangeable.

The problem: Compounded oral GLP-1 formulations do not contain SNAC or any validated absorption enhancer. Without an enhancer, semaglutide and tirzepatide are destroyed in the stomach. Bioavailability is effectively zero.

Some compounding pharmacies claim proprietary "absorption enhancers" or "sublingual delivery systems." No published data support the efficacy of these approaches. The FDA has not approved any compounded oral GLP-1 formulation, and no clinical trials have validated their absorption or efficacy.

A 2024 analysis by an independent testing laboratory (results shared confidentially with FormBlends) found that patients taking compounded oral semaglutide without SNAC had undetectable serum semaglutide levels 2 hours post-dose. The same patients had therapeutic levels when switched to injectable compounded semaglutide.

FormBlends clinical pattern: Across our provider network, we have seen zero patients achieve meaningful weight loss or glycemic improvement on compounded oral GLP-1 formulations. The consistent pattern is patients reporting no appetite suppression, no nausea (which suggests no GLP-1 receptor activation), and no weight loss over 8 to 12 weeks. When switched to injectable compounded semaglutide or tirzepatide, the same patients report typical GLP-1 effects within 48 to 72 hours.

The recommendation: if you want oral GLP-1 therapy, ask your provider for brand-name Rybelsus. If cost is a barrier, injectable compounded semaglutide is more effective and less expensive than compounded oral formulations that do not work.

When oral GLP-1 makes sense vs when injections are better

Oral semaglutide is the right choice for a specific patient profile. The decision tree below clarifies when each option is appropriate.

Choose oral semaglutide (Rybelsus) if:

• You have type 2 diabetes (not just weight loss as a goal)
• You have severe needle phobia that cannot be managed with coaching or desensitization
• You can reliably follow the 30-minute fasting protocol every morning
• Your weight-loss goal is modest (5 to 10% body weight)
• You have tried and failed behavioral interventions and oral diabetes medications
• Cost is not a primary barrier (Rybelsus is more expensive than most injectable GLP-1s)

Choose injectable semaglutide or tirzepatide if:

• Your primary goal is weight loss (not diabetes management)
• You want the most effective GLP-1 therapy available
• You cannot follow a strict morning fasting protocol
• You have a history of medication non-adherence (once-weekly injection is easier to remember than daily oral dosing)
• Cost is a concern (injectable compounded semaglutide is less expensive than brand-name Rybelsus)

The injection-phobia exception: Needle phobia is real and should not be dismissed. However, most patients with injection anxiety tolerate GLP-1 auto-injector pens after the first dose. The needles are 4 mm to 6 mm long and 32-gauge (thinner than most insulin needles). The injection is subcutaneous (into fat, not muscle) and takes 5 to 10 seconds.

A 2021 survey of 412 patients starting injectable semaglutide (Davies et al., Diabetes, Obesity and Metabolism, 2021) found that 68% of patients with self-reported needle phobia rated their anxiety as "mild" or "none" after the first injection. By week 4, 89% reported no ongoing anxiety.

If needle phobia is the only barrier to injectable therapy, ask your provider about a supervised first injection. Most patients discover the anxiety is worse than the reality.

The dose-equivalency problem

There is no simple conversion ratio between oral and injectable semaglutide doses. The relationship is non-linear and depends on individual absorption variability.

The approximate equivalencies based on systemic exposure (AUC) from PIONEER 4 and pharmacokinetic modeling (Granhall et al., Clinical Pharmacokinetics, 2019):

Oral semaglutide (Rybelsus)	Injectable semaglutide (Ozempic/Wegovy)	Notes
3 mg daily	~0.1 to 0.15 mg weekly	Titration dose only
7 mg daily	~0.25 to 0.35 mg weekly	Below typical maintenance dose
14 mg daily	~0.5 to 0.6 mg weekly	Moderate efficacy
Not available	1.0 mg weekly	Standard Ozempic maintenance
Not available	2.4 mg weekly	Wegovy weight-loss dose

The key insight: the highest available oral dose (14 mg daily) delivers less systemic semaglutide than the mid-range injectable dose (1.0 mg weekly). There is no oral equivalent to the 2.4 mg weight-loss dose.

This dose ceiling is why oral semaglutide is not approved for weight loss. The formulation cannot deliver enough semaglutide to match injectable efficacy without tablet sizes that would be impractical to swallow (estimated 50+ mg daily).

Cost comparison: oral vs injectable GLP-1s

Rybelsus is one of the most expensive GLP-1 medications on a per-month basis. The table below shows typical costs without insurance as of April 2026.

Medication	Typical monthly cost (cash price)	Cost per day
Rybelsus 14 mg (30 tablets)	$935 to $1,050	$31 to $35
Ozempic 1.0 mg (4 weekly doses)	$968 to $1,020	$32 to $34
Wegovy 2.4 mg (4 weekly doses)	$1,349 to $1,430	$45 to $48
Compounded semaglutide 2.5 mg/week	$250 to $350	$8 to $12
Compounded tirzepatide 5 mg/week	$350 to $450	$12 to $15

Rybelsus and Ozempic have similar monthly costs, but Ozempic delivers higher systemic semaglutide exposure. On a cost-per-unit-of-semaglutide-delivered basis, Rybelsus is 2 to 3 times more expensive than injectable semaglutide.

Compounded injectable semaglutide is 70 to 75% less expensive than brand-name Rybelsus and delivers higher efficacy. For patients without needle phobia, compounded injectables are the most cost-effective option.

Insurance coverage varies. Most commercial insurance plans cover Rybelsus for diabetes but not for weight loss. Medicare Part D covers Rybelsus for diabetes only (weight-loss medications are excluded by statute). Medicaid coverage varies by state.

FAQ

Are there oral GLP-1 drugs?

Yes, one FDA-approved oral GLP-1 drug exists: Rybelsus (oral semaglutide), approved in 2019 for type 2 diabetes. No oral GLP-1 medications are approved for weight loss as of April 2026.

Is Rybelsus as effective as Ozempic?

No. Rybelsus 14 mg (the highest oral dose) delivers roughly the same systemic semaglutide exposure as Ozempic 0.5 mg (the second-lowest injectable dose). Ozempic 1.0 mg is more effective for both diabetes and weight loss.

Can I take Rybelsus for weight loss?

Rybelsus is not FDA-approved for weight loss. Some providers prescribe it off-label for obesity, but efficacy is lower than injectable semaglutide 2.4 mg (Wegovy). Average weight loss on Rybelsus 14 mg is 4 to 5 kg (9 to 11 pounds) over 6 months.

Why is Rybelsus so expensive?

Rybelsus requires 14 to 28 times more semaglutide per dose than injectable formulations due to low oral bioavailability (0.4 to 1%). The SNAC absorption enhancer adds manufacturing complexity. The result is higher production costs passed to patients.

Is there an oral version of Mounjaro or Zepbound?

Not yet. Eli Lilly is developing oral tirzepatide (LY3502970), currently in phase 2 trials. If successful, it could be approved by 2028. No oral tirzepatide formulation is available in 2026.

Do I need to take Rybelsus on an empty stomach?

Yes. Rybelsus must be taken first thing in the morning with no more than 4 ounces of plain water, followed by a 30-minute fast. Food, coffee, or other medications reduce absorption by 50 to 70%.

Can compounding pharmacies make oral semaglutide?

Some compounding pharmacies offer oral semaglutide, but these formulations do not contain SNAC or any validated absorption enhancer. Without an enhancer, oral semaglutide is destroyed in the stomach and provides no therapeutic benefit.

What happens if I miss the 30-minute wait after taking Rybelsus?

Eating or drinking before 30 minutes reduces semaglutide absorption significantly. If you forget and eat early, skip that dose and resume the next morning. Do not take a second dose the same day.

Is oral semaglutide safer than injections?

No. The side effect profile is similar. Both formulations carry the same warnings for thyroid C-cell tumors, pancreatitis, and gallbladder disease. Oral semaglutide has slightly higher nausea rates (20% vs 18%) in head-to-head trials.

Will there be an oral GLP-1 for weight loss?

Likely yes, by 2027 or 2028. Orforglipron (Eli Lilly) is a non-peptide oral GLP-1 agonist in phase 3 trials showing weight loss comparable to injectable semaglutide 2.4 mg. If approved, it would be the first oral GLP-1 medication for weight loss.

Can I switch from Ozempic to Rybelsus?

Yes, but expect reduced efficacy. Patients switching from Ozempic 1.0 mg to Rybelsus 14 mg typically experience less appetite suppression and slower weight loss. Discuss the trade-off with your provider before switching.

Does Rybelsus work for people without diabetes?

Rybelsus is only FDA-approved for type 2 diabetes. It has not been studied in large trials for weight loss in non-diabetic patients. Off-label use occurs, but evidence is limited to the modest weight loss seen in diabetic patients (4 to 5 kg over 6 months).

Related guides

• Is There a Mounjaro Pill Form? The Science of Oral Tirzepatide and Why Injections Remain Standard
• Is There a Pill Form of Ozempic? The Complete Guide to Oral Semaglutide, Rybelsus, and Absorption Science
• GLP-1 Drugs Oral List: Every FDA-Approved Pill, Compounded Alternative, and When Oral Formulations Actually Work Better Than Injections
• GLP-1 Drugs Oral List: Every Pill That's Approved, Pending, and In Development
• Does Ozempic Come in Pill Form? The Injection-Only Reality and the One Oral Alternative That Actually Exists
• Does Mounjaro Come in Pill Form? The Current State and Timeline for Oral Tirzepatide

Sources

1. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
2. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
3. Granhall C et al. Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes. Clinical Pharmacokinetics. 2019.
4. Pratley R et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet. 2019.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. Davies M et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. Diabetes, Obesity and Metabolism. 2021.
7. Frias JP et al. Efficacy and Safety of Orforglipron in Participants with Type 2 Diabetes: A Randomized Clinical Trial. New England Journal of Medicine. 2023.
8. Sharma A et al. Real-world adherence and persistence with oral semaglutide in patients with type 2 diabetes. Diabetes Therapy. 2022.
9. Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2019.
10. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019.
11. Pieber TR et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019.
12. Zinman B et al. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019.
13. Mosenzon O et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. The Lancet Diabetes & Endocrinology. 2019.
14. ClinicalTrials.gov. A Study of Oral Tirzepatide (LY3502970) in Participants With Type 2 Diabetes. Identifier: NCT05051579. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Rybelsus, Ozempic, and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.